Genomic Vision Stock

Genomic Vision PP&E per Employee

The PP&E per Employee of Genomic Vision (GV.PA) as of Sep 8, 2026 is 40,192.31 EUR. In the previous year, PP&E per Employee was 48,730.77 EUR — a change of -17.52% (lower).

PP&E per Employee

40,192.31EUR

YoY

-17.52%

Last updated:

PP&E per Employee of Genomic Vision is 2026 40,192.31 EUR. PP&E per Employee of Genomic Vision was 2025 48,730.77 EUR. It decreases by -17.52% lower compared to the previous year.

The Genomic Vision PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
101,153.85 EUR
Jan 1, 2016
81,269.23 EUR
Jan 1, 2017
56,346.15 EUR
Jan 1, 2018
34,923.08 EUR
Jan 1, 2019
22,692.31 EUR
Jan 1, 2020
60,576.92 EUR
Jan 1, 2021
48,730.77 EUR
Jan 1, 2022
40,192.31 EUR
The Genomic Vision PP&E per Employee history
YEARPP&E per EmployeeYoY
40,192.31EUR-17.52%
48,730.77EUR-19.56%
60,576.92EUR+166.95%
22,692.31EUR-35.02%
34,923.08EUR-38.02%
56,346.15EUR-30.67%
81,269.23EUR-19.66%
101,153.85EUR+202.30%
33,461.54EUR
Access this data via the Eulerpool API

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomic Vision stock

PP&E per Employee of Genomic Vision is 40,192.31 EUR in 2026.

PP&E per Employee of Genomic Vision changed from 48,730.77 EUR to 40,192.31 EUR, representing a -17.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Genomic Vision historically and in real time.

Access this data via the Eulerpool API

Workforce — Genomic Vision

All Key Metrics — Genomic Vision